Immuneering Corporation (IMRX) Stock

Immuneering Corporation (IMRX) is a Healthcare stock trading at $4.39 (as of 2026-06-18), with a market capitalization of $373.08M and a trailing P/E of -4.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Immuneering Corporation is a biopharmaceutical company developing oncology and neuroscience product candidates. Its pipeline includes IMM-1-104, a dual MEK inhibitor for multiple cancer types, and IMM-6-415 for solid tumors, along with additional discovery-stage oncology programs targeting the MAPK and mTOR pathways and two neuroscience programs.

Valuation — source: SEC EDGAR (first-party)
Price	$4.39
Market Cap	$373.08M
P/E Ratio	-4.2
EV / EBITDA	-4.0
Price / Book	1.38
Price / Sales	71.98
DCF Value (model)	$-14.67
DCF Upside vs Price	-434.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$3.04M
Net Margin	-1843.3%
Return on Equity	-26.4%
Current Ratio	32.45
Revenue Growth (YoY)	17.2%
EPS Growth (YoY)	-37.7%
FCF Growth (YoY)	-17.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	6.92 (safe)

Valuation vs Sector & Industry
Stock P/E	-4.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-119.9%
vs Industry	-124.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FMR LLC ($51.11M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Benjamin J. Zeskind
Employees	54
Country	US
IPO Date	2021-07-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.